Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Chang Hyun | - |
dc.contributor.author | Lee, Hyung Keun | - |
dc.contributor.author | Kim, Mee Kum | - |
dc.contributor.author | Kim, Eun Chul | - |
dc.contributor.author | Kim, Jae Yong | - |
dc.contributor.author | Kim, Tae-im | - |
dc.contributor.author | Kim, Hong Kyun | - |
dc.contributor.author | Song, Jong Suk | - |
dc.contributor.author | Yoon, Kyung Chul | - |
dc.contributor.author | Lee, Do Hyung | - |
dc.contributor.author | Chung, Tae-Young | - |
dc.contributor.author | Choi, Chul Young | - |
dc.contributor.author | Kim, Hyun Seung | - |
dc.date.accessioned | 2021-09-01T13:44:05Z | - |
dc.date.available | 2021-09-01T13:44:05Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-06-17 | - |
dc.identifier.issn | 1471-2415 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/64755 | - |
dc.description.abstract | BackgroundThis study is aim to compare the clinical effectiveness between the two most prominent dry eye disease (DED)-specific eye drops, 0.05% cyclosporine (CN) and 3% diquafosol (DQ).MethodsThis is a multi-centered, randomized, masked, prospective clinical study. A total of 153 DED patients were randomly allocated to use CN twice per day or DQ six times daily. Cornea and conjunctival staining scores (NEI scale), tear break-up time (TBUT), Schirmer test scores, and ocular surface disease index (OSDI) score were measured at baseline, 4 and 12weeks after treatment.ResultsAt 12weeks after treatment, NEI scaled scores were significantly reduced from the baseline by -6.60 for CN and-6.63 for DQ group (all P<0.0001, P=0.9739 between groups). TBUT and Schirmer values for CN were significantly improved from the baseline at 4 and 12weeks (P=0.0034, P<0.0001 for TBUT, P=0.0418, P=0.0031 for Schirmer test). However, for DQ, TBUT showed significant improvement at 12weeks only (P=0.0281). Mean OSDI score differences from the baseline to 12weeks were improved by -13.0319.63 for CN and-16.1120.87 for DQ, respectively (all P<0.0001, P=0.854 between groups). Regarding drug compliance, the mean instillation frequency of CN was less than that of DQ (P<0.001). There were no statistically significant intergroup differences in safety evaluation.Conclusions The level of improvement regarding NEI, TBUT, and OSDI scores were not significantly different between the two treatment groups. However, with regards to the early improvement of TBUT and patient compliance, patients using CN improved faster and with greater adherence to drug usage than did those treated with DQ.Trial registration KCT0002180, retrospectively registered on 23 December 2016. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.subject | SODIUM HYALURONATE | - |
dc.subject | TOPICAL CYCLOSPORINE | - |
dc.subject | OPHTHALMIC SOLUTION | - |
dc.subject | DISEASE | - |
dc.subject | EFFICACY | - |
dc.subject | 0.1-PERCENT | - |
dc.subject | SAFETY | - |
dc.subject | PATHOPHYSIOLOGY | - |
dc.subject | BIOAVAILABILITY | - |
dc.subject | CLASSIFICATION | - |
dc.title | Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Jong Suk | - |
dc.identifier.doi | 10.1186/s12886-019-1136-8 | - |
dc.identifier.wosid | 000471892300001 | - |
dc.identifier.bibliographicCitation | BMC OPHTHALMOLOGY, v.19 | - |
dc.relation.isPartOf | BMC OPHTHALMOLOGY | - |
dc.citation.title | BMC OPHTHALMOLOGY | - |
dc.citation.volume | 19 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Ophthalmology | - |
dc.relation.journalWebOfScienceCategory | Ophthalmology | - |
dc.subject.keywordPlus | SODIUM HYALURONATE | - |
dc.subject.keywordPlus | TOPICAL CYCLOSPORINE | - |
dc.subject.keywordPlus | OPHTHALMIC SOLUTION | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | 0.1-PERCENT | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | PATHOPHYSIOLOGY | - |
dc.subject.keywordPlus | BIOAVAILABILITY | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordAuthor | Dry eye disease | - |
dc.subject.keywordAuthor | Cyclosporine | - |
dc.subject.keywordAuthor | Diquafosol | - |
dc.subject.keywordAuthor | Tear break-up time | - |
dc.subject.keywordAuthor | Schirmer&apos | - |
dc.subject.keywordAuthor | s test | - |
dc.subject.keywordAuthor | Ocular surface disease index | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.